Social Anxiety Disorder (SAD) - Drug Pipeline Landscape, 2023
Description
Social Anxiety Disorder is a significant and persistent fear of social and performance-related situations it is one of the most common mental disorders.
Social Anxiety Disorder is caused by the complex interaction of biological and environmental factors like inherited traits, brain structure (amygdala may play a role in controlling the fear response), and environment.
The main symptoms of social anxiety disorders are a person's inability to work, difficulty maintaining friendships, and family relationships avoiding lifestyle activities like dining out and traveling.
Social anxiety disorder is diagnosed by scale scorings like the liebowitz social anxiety scale, subjective units of distress scale, state-trait anxiety inventory, and negative self-statements during the public speaking subscale (SSPS-N).
Social anxiety disorder is treated by cognitive behavioral therapy and drugs like antidepressants.
Report Highlights
Global Insight Service’s, Social Anxiety Disorders (SAD) - Drug Pipeline Landscape, 2023 report provides an overview of the Social Anxiety Disorders (SAD) pipeline drugs. This report covers detailed insights on Social Anxiety Disorders (SAD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Social Anxiety Disorders (SAD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Social Anxiety Disorder is caused by the complex interaction of biological and environmental factors like inherited traits, brain structure (amygdala may play a role in controlling the fear response), and environment.
The main symptoms of social anxiety disorders are a person's inability to work, difficulty maintaining friendships, and family relationships avoiding lifestyle activities like dining out and traveling.
Social anxiety disorder is diagnosed by scale scorings like the liebowitz social anxiety scale, subjective units of distress scale, state-trait anxiety inventory, and negative self-statements during the public speaking subscale (SSPS-N).
Social anxiety disorder is treated by cognitive behavioral therapy and drugs like antidepressants.
Report Highlights
Global Insight Service’s, Social Anxiety Disorders (SAD) - Drug Pipeline Landscape, 2023 report provides an overview of the Social Anxiety Disorders (SAD) pipeline drugs. This report covers detailed insights on Social Anxiety Disorders (SAD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Social Anxiety Disorders (SAD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
81 Pages
- List of Tables
- List of Figures
- 1. Introduction
- 1.1 Social Anxiety Disorder (SAD) – Pipeline Drugs, 2023-Coverage
- 2. Disease Overview – Social Anxiety Disorder (SAD)
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Social Anxiety Disorder (SAD) – Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs – Phase III
- 5.1.1 BHV-0223
- 5.1.2 PH94B
- 5.2 Clinical Stage Drugs – Phase II
- 5.2.1 BNC210
- 5.2.2 Cannabidiol
- 5.2.3 FKW 00GA
- 5.2.4 RLS103
- 5.2.5 VQW-765
- 5.3 Clinical Stage Drugs – Phase I
- 5.3.1 Prazosin/Propranolol
- 5.3.2 R(-)MDMA
- 5.4 Clinical Stage Drugs – IND/CTA Filed
- 5.4.1 A-1002-N5S
- 5.5 Clinical Stage Drugs – Discovery
- 5.5.1 Dimethyltryptamine
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Ananda Scientific
- 9.2 Biohaven Pharmaceuticals Inc
- 9.3 Bionomics Limited
- 9.4 Fabre-Kramer Pharmaceuticals
- 9.5 Mindmed
- 9.6 Otsuka Pharmaceutical Development & Commercialization Inc
- 9.7 Psilera
- 9.8 Receptor Life Sciences
- 9.9 Tilray
- 9.10 Vanda Pharmaceuticals
- 9.11 VistaGen Therapeutics Inc
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products Under Development for Social Anxiety Disorder (SAD)
- Table 1.2 Number of Products Under Development by Companies
- Table 1.3 Products Under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - PH94B/VistaGen Therapeutics Inc
- Table 2.2 Clinical Trial Details - BHV-0223/Biohaven Pharmaceuticals Inc
- Table 2.3 Clinical Trial Details - BNC210/Bionomics Limited
- Table 2.4 Clinical Trial Details - Cannabidiol /Tilray
- Table 2.5 Clinical Trial Details - Prazosin/Propranolol/Otsuka Pharmaceutical Development &Commercialization Inc
- Table 2.6 Clinical Trial Details - RLS103/Receptor Life Sciences
- Table 2.7 Clinical Trial Details - VQW-765/Vanda Pharmaceuticals
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Social Anxiety Disorder (SAD), 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Social Anxiety Disorder (SAD), 2023
- Figure 1.3 Products by Top 5 Mechanism of Action for Social Anxiety Disorder (SAD), 2023
- Figure 1.4 Products by Top 5 Molecule Type for Social Anxiety Disorder (SAD), 2023
- Figure 1.5 Products by Top 5 Route of Administration for Social Anxiety Disorder (SAD), 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
